pdating for events
that occur after the date of this press release.
PALATIN TECHNOLOGIES, INC.
Consolidated Statement of Operations Data
(unaudited)
Three Months Ended September 30,
2007 2006
REVENUES:
Licenses, grants and contracts $ 8,977,731 $ 4,935,102
OPERATING EXPENSES:
Research and development 7,943,877 12,125,252
General and administrative 1,659,010 1,560,922
Total operating expenses 9,602,887 13,686,174
Loss from operations (625,156) (8,751,072)
OTHER INCOME (EXPENSE):
Investment income 396,621 324,235
Interest expense (18,229) (10,066)
Total other income, net 378,392 314,169
NET LOSS $(246,764) $(8,436,903)
Basic and diluted net loss per
common share $ (0.00) $(0.12)
Weighted average number of common
shares outstanding used in computing
basic and diluted net loss per
common share 85,177,298 70,878,521
PALATIN TECHNOLOGIES, INC.
Consolidated Balance Sheet Data
(unaudited)
September 30, 2007 June 30, 2007
ASSETS
Current assets:
Cash and cash equivalents $24,305,501 $31,447,615
Available-for-sale investments 2,339,456 2,323,642
Accounts receivable 460,269 607,841
Prepaid expenses and other current
'/>"/>
SOURCE Palatin Technologies, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program2.
Palatin Technologies Refutes Competitive Technologies Contention of Material Breach3.
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 20074.
Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 20075.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering6.
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel7.
Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices8.
Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer9.
Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq10.
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split11.
Neurobiological Technologies, Inc. (Nasdaq: NTIID)